Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (UM1-AI068634)
Bill and Melinda Gates Foundation (INV-002039, INV-002039)
- License Information
-
More Information
Article History
Received: 23 October 2023
Accepted: 21 February 2024
First Online: 12 March 2024
Declarations
:
: Participants in the REMoxTB trial all provided written or witnessed oral informed consent. The ethics committee at University College London and all national and local ethics committees approved the study. The Food and Drug Administration, the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte), and the national regulatory authorities of the countries in which the trial was conducted reviewed and approved the protocol.
: Not applicable.
: The authors declare that they have no competing interests.
